Usha Perepu

Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial

Robert D. McBane, Waldemar E. Wysokiński, Jennifer Le‐Rademacher et al. · Journal of Thrombosis and Haemostasis · 2019 · 554 citations

Thrombosis, Venous Thrombosis, Adam Vte Trial +6

Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID‐19: A multi‐center, open‐label, randomized controlled trial

Usha Perepu, Isaac Chambers, Abdul Wahab et al. · Journal of Thrombosis and Haemostasis · 2021 · 168 citations · Full text

Long Covid, Clinical Trials, Severe Covid‐19 +3

Apixaban, Dalteparin, in Active Cancer Associated Venous Thromboembolism, the ADAM VTE Trial

Robert D. McBane, Waldemar E. Wysokiński, Jennifer Le‐Rademacher et al. · Blood · 2018 · 52 citations

Extending venous thromboembolism secondary prevention with apixaban in cancer patients. The EVE trial

Robert D. McBane, Charles L. Loprinzi, Tyler Zemla et al. · Journal of Thrombosis and Haemostasis · 2024 · 49 citations · Full text

Thrombosis, Venous Disease, Oncology +8

Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression

Sean Tracy, Thomas M. Habermann, Andrew L. Feldman et al. · Haematologica · 2017 · 23 citations · Full text